GLPGF
Lakefront Biotherapeutics NV
Price Chart
Latest Quote
$48.70
+14.70 (+43.24%)
Current Price
| Previous Close | $34.00 |
| Open | $26.20 |
| Day High | $26.20 |
| Day Low | $26.20 |
| Volume | 190 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 65.86M |
| Total Debt | $7.32M |
| Cash Equivalents | $3.39B |
| Revenue | $1.19B |
| Net Income | $554.78M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.21B |
| P/E Ratio | 5.74 |
| EPS (TTM) | $8.49 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.13B |
| Sales | $1.19B |
| Income | $554.78M |
| Book/sh | $56.59 |
| Cash/sh | $45.28 |
Financial Ratios
| Quick Ratio | 30.23 |
| Current Ratio | 30.48 |
| Debt/Eq | 0.20 |
Returns & Margins
| ROA | 10.66% |
| ROE | 16.26% |
| Gross Margin | 68.53% |
| Operating Margin | -982.92% |
| Profit Margin | 46.83% |
Ownership
| Insider Ownership | 25.36% |
| Institutional Ownership | 32.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 3.07 |
| P/B | 0.86 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $28.08 |
| SMA50 | $28.81 |
| SMA200 | $31.88 |
| RSI | nan |
| Shares Float | 44.54M |
| Volatility | 0.13 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -15.60% |
| 6 Months | -10.26% |
| YTD | -10.26% |
| Year | +2.11% |
| 3 Years | -26.11% |
| 5 Years | -64.34% |
| 10 Years | -32.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $28.08 | 0 |
| 2026-06-22 | $28.08 | 0 |
| 2026-06-18 | $28.08 | 0 |
| 2026-06-17 | $28.08 | 0 |
| 2026-06-16 | $28.08 | 0 |
| 2026-06-15 | $28.08 | 0 |
| 2026-06-12 | $28.08 | 0 |
| 2026-06-11 | $28.08 | 0 |
| 2026-06-10 | $28.08 | 0 |
| 2026-06-09 | $28.08 | 0 |
| 2026-06-08 | $28.08 | 0 |
| 2026-06-05 | $28.08 | 0 |
| 2026-06-04 | $28.08 | 0 |
| 2026-06-03 | $28.08 | 0 |
| 2026-06-02 | $28.08 | 0 |
| 2026-06-01 | $28.08 | 0 |
| 2026-05-29 | $28.08 | 0 |
| 2026-05-28 | $28.08 | 0 |
| 2026-05-27 | $28.08 | 0 |
| 2026-05-26 | $28.08 | 0 |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
đ° Latest News
Lakefront Biotherapeutics (ENXTAM:LKFT) Stock After Recent Gains Still A Recovery Opportunity?
Simply Wall St. âĸ 2026-06-14T02:11:37Z
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline
Insider Monkey âĸ 2026-06-07T04:39:16Z
Galapagos Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T20:58:37Z
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
Insider Monkey âĸ 2026-04-24T13:43:58Z
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Insider Monkey âĸ 2026-04-04T12:16:40Z
Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials
MarketBeat âĸ 2026-03-31T13:26:19Z
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
Simply Wall St. âĸ 2026-03-31T08:16:30Z
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
Insider Monkey âĸ 2026-03-27T00:55:02Z
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
Zacks âĸ 2026-03-24T19:03:00Z
Gilead to buy Ouro Medicines for up to $2.2 billion
Investing.com âĸ 2026-03-23T22:58:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,536,000 | $0 | $0 | $1,629,000 |
| Cost Of Revenue | $34,863,000 | $0 | $0 | $1,629,000 |
| Total Revenue | $275,649,000 | $239,724,000 | $241,249,000 | $234,384,000 |
| Operating Revenue | $275,649,000 | $239,724,000 | $241,249,000 | $234,384,000 |
| Expenses | ||||
| Interest Expense | $911,000 | $1,770,000 | $9,155,000 | $11,592,000 |
| Total Expenses | $463,987,000 | $327,987,000 | $372,306,000 | $405,949,000 |
| Other Income Expense | $95,795,000 | $16,252,000 | $51,499,000 | $61,462,000 |
| Net Non Operating Interest Income Expense | $89,458,000 | $77,636,000 | $8,709,000 | $-9,296,000 |
| Total Other Finance Cost | $-596,000 | $202,000 | $230,000 | $569,000 |
| Interest Expense Non Operating | $911,000 | $1,770,000 | $9,155,000 | $11,592,000 |
| Operating Expense | $429,124,000 | $327,987,000 | $372,306,000 | $405,949,000 |
| Other Operating Expenses | $-16,387,000 | $-23,650,000 | $-9,389,000 | $-20,164,000 |
| Selling And Marketing Expense | $2,813,000 | $1,776,000 | $1,267,000 | $1,802,000 |
| General And Administrative Expense | $94,067,000 | $92,476,000 | $102,043,000 | $87,433,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,282,000 | $-3,988,000 | $-71,421,000 | $-120,791,000 |
| Net Interest Income | $89,458,000 | $77,636,000 | $8,709,000 | $-9,296,000 |
| Interest Income | $89,773,000 | $79,608,000 | $18,094,000 | $2,865,000 |
| Normalized Income | $-76,960,050 | $-16,827,080 | $-112,105,210 | $-165,658,260 |
| Net Income From Continuing And Discontinued Operation | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Total Operating Income As Reported | $-188,338,000 | $-88,263,000 | $-131,056,000 | $-171,568,000 |
| Net Income Common Stockholders | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Net Income | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Net Income Including Noncontrolling Interests | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Net Income Discontinuous Operations | $75,364,000 | $215,685,000 | $-146,570,000 | $17,560,000 |
| Net Income Continuous Operations | $-1,282,000 | $-3,988,000 | $-71,421,000 | $-120,791,000 |
| Pretax Income | $-3,085,000 | $5,625,000 | $-70,849,000 | $-119,402,000 |
| Interest Income Non Operating | $89,773,000 | $79,608,000 | $18,094,000 | $2,865,000 |
| Operating Income | $-188,338,000 | $-88,263,000 | $-131,057,000 | $-171,565,000 |
| Depreciation Amortization Depletion Income Statement | $13,172,000 | $16,091,000 | $8,588,000 | $16,375,000 |
| Depreciation And Amortization In Income Statement | $13,172,000 | $16,091,000 | $8,588,000 | $16,375,000 |
| Depreciation Income Statement | $13,172,000 | $16,091,000 | $8,588,000 | $16,375,000 |
| Gross Profit | $240,786,000 | $239,724,000 | $241,249,000 | $483,217,000 |
| Per Share | ||||
| Diluted EPS | $1.12 | $3.21 | $-3.32 | $-1.58 |
| Basic EPS | $1.12 | $3.21 | $-3.32 | $-1.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $20,116,950 | $3,412,920 | $10,814,790 | $16,594,740 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-52,470,000 | $34,785,000 | $-47,627,000 | $-134,636,000 |
| Total Unusual Items | $95,795,000 | $16,252,000 | $51,499,000 | $61,462,000 |
| Total Unusual Items Excluding Goodwill | $95,795,000 | $16,252,000 | $51,499,000 | $61,462,000 |
| Reconciled Depreciation | $45,499,000 | $43,642,000 | $65,566,000 | $34,636,000 |
| EBITDA (Bullshit earnings) | $43,325,000 | $51,037,000 | $3,872,000 | $-73,174,000 |
| EBIT | $-2,174,000 | $7,395,000 | $-61,694,000 | $-107,810,000 |
| Diluted Average Shares | $66,144,643 | $65,884,000 | $65,659,940 | $65,500,000 |
| Basic Average Shares | $66,144,643 | $65,884,000 | $65,659,940 | $65,500,000 |
| Diluted NI Availto Com Stockholders | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Tax Provision | $-1,803,000 | $9,613,000 | $572,000 | $1,389,000 |
| Gain On Sale Of Security | $95,795,000 | $16,252,000 | $51,499,000 | $61,462,000 |
| Research And Development | $335,459,000 | $241,294,000 | $269,797,000 | $320,503,000 |
| Selling General And Administration | $96,880,000 | $94,252,000 | $103,310,000 | $89,235,000 |
| Other Gand A | $34,864,000 | $23,381,000 | $23,814,000 | $25,360,000 |
| Salaries And Wages | $59,203,000 | $69,095,000 | $78,229,000 | $62,073,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,662,067,000 | $2,598,103,000 | $2,309,860,000 | $2,583,259,000 |
| Total Assets | $4,135,719,000 | $4,357,396,000 | $4,734,351,000 | $5,193,160,000 |
| Total Non Current Assets | $796,269,000 | $495,807,000 | $497,501,000 | $331,306,000 |
| Other Non Current Assets | $3,251,000 | $5,851,000 | $5,778,000 | $2,472,000 |
| Non Current Prepaid Assets | $5,457,000 | $10,219,000 | $0 | - |
| Non Current Deferred Assets | $1,474,000 | $1,126,000 | $1,363,000 | $4,032,000 |
| Non Current Deferred Taxes Assets | $1,474,000 | $1,126,000 | $1,363,000 | $4,032,000 |
| Non Current Accounts Receivable | $175,194,000 | $141,252,000 | $119,941,000 | $127,186,000 |
| Investmentin Financial Assets | $200,182,000 | $0 | $0 | $0 |
| Goodwill And Other Intangible Assets | $234,872,000 | $197,463,000 | $216,166,000 | $60,103,000 |
| Other Intangible Assets | $164,862,000 | $127,906,000 | $146,353,000 | $60,103,000 |
| Current Assets | $3,339,450,000 | $3,861,589,000 | $4,236,850,000 | $4,861,854,000 |
| Assets Held For Sale Current | $11,115,000 | $22,085,000 | $0 | $0 |
| Current Deferred Assets | $30,214,000 | $14,632,000 | $12,029,000 | $9,306,000 |
| Restricted Cash | $41,163,000 | $0 | - | - |
| Prepaid Assets | $103,000 | $738,000 | $488,000 | $202,000 |
| Inventory | $51,192,000 | $73,978,000 | $52,925,000 | $20,569,000 |
| Receivables | $88,090,000 | $65,655,000 | $77,344,000 | $128,601,000 |
| Other Receivables | $55,619,000 | $48,161,000 | $49,150,000 | $36,815,000 |
| Accounts Receivable | $32,471,000 | $17,494,000 | $28,194,000 | $91,786,000 |
| Cash Cash Equivalents And Short Term Investments | $3,117,573,000 | $3,684,501,000 | $4,094,062,000 | $4,703,177,000 |
| Cash And Cash Equivalents | $64,239,000 | $166,803,000 | $508,117,000 | $2,233,368,000 |
| Cash Equivalents | $0 | $95,000,000 | $50,000,000 | $1,007,508,000 |
| Cash Financial | $64,239,000 | $71,803,000 | $458,117,000 | $1,225,860,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | - | $13,575,000 | $0 | $0 |
| Other Current Assets | - | - | $2,000 | $-1,000 |
| Debt | ||||
| Total Debt | $11,722,000 | $9,596,000 | $21,901,000 | $26,859,000 |
| Long Term Debt And Capital Lease Obligation | $8,243,000 | $4,944,000 | $14,692,000 | $19,655,000 |
| Current Debt And Capital Lease Obligation | $3,479,000 | $4,652,000 | $7,209,000 | $7,204,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,238,780,000 | $1,561,830,000 | $2,208,325,000 | $2,549,798,000 |
| Total Non Current Liabilities Net Minority Interest | $903,699,000 | $1,133,607,000 | $1,685,787,000 | $1,983,324,000 |
| Other Non Current Liabilities | $33,821,000 | $31,570,000 | $21,808,000 | $7,134,000 |
| Non Current Deferred Liabilities | $859,536,000 | $1,094,800,000 | $1,643,747,000 | $1,944,836,000 |
| Non Current Deferred Taxes Liabilities | $20,660,000 | $23,607,000 | $20,148,000 | $0 |
| Current Liabilities | $335,081,000 | $428,223,000 | $522,538,000 | $566,474,000 |
| Other Current Liabilities | $5,000 | $32,044,000 | $8,505,000 | $204,000 |
| Current Deferred Liabilities | $232,476,000 | $256,270,000 | $365,631,000 | $419,866,000 |
| Payables And Accrued Expenses | $99,121,000 | $135,257,000 | $141,193,000 | $139,200,000 |
| Payables | $98,029,000 | $134,709,000 | $140,542,000 | $136,086,000 |
| Total Tax Payable | $249,000 | $56,000 | $1,022,000 | $1,782,000 |
| Accounts Payable | $97,780,000 | $134,653,000 | $133,298,000 | $134,304,000 |
| Other Payable | - | - | $6,222,000 | - |
| Equity | ||||
| Common Stock Equity | $2,896,939,000 | $2,795,566,000 | $2,526,026,000 | $2,643,362,000 |
| Total Equity Gross Minority Interest | $2,896,939,000 | $2,795,566,000 | $2,526,026,000 | $2,643,362,000 |
| Stockholders Equity | $2,896,939,000 | $2,795,566,000 | $2,526,026,000 | $2,643,362,000 |
| Gains Losses Not Affecting Retained Earnings | $314,000 | $-7,091,000 | $-6,446,000 | $-11,899,000 |
| Other Equity Adjustments | $-3,158,000 | $-5,890,000 | $-4,853,000 | $-10,177,000 |
| Retained Earnings | $-134,306,000 | $-228,274,000 | $-496,689,000 | $-367,205,000 |
| Long Term Equity Investment | $52,941,000 | $13,575,000 | - | - |
| Other | ||||
| Ordinary Shares Number | $65,897,071 | $65,897,071 | $65,835,511 | $65,552,721 |
| Share Issued | $65,897,071 | $65,897,071 | $65,835,511 | $65,552,721 |
| Tangible Book Value | $2,662,067,000 | $2,598,103,000 | $2,309,860,000 | $2,583,259,000 |
| Invested Capital | $2,896,939,000 | $2,795,566,000 | $2,526,026,000 | $2,643,362,000 |
| Working Capital | $3,004,369,000 | $3,433,366,000 | $3,714,312,000 | $4,295,380,000 |
| Capital Lease Obligations | $11,722,000 | $9,596,000 | $21,901,000 | $26,859,000 |
| Total Capitalization | $2,896,939,000 | $2,795,566,000 | $2,526,026,000 | $2,643,362,000 |
| Foreign Currency Translation Adjustments | $3,472,000 | $-1,201,000 | $-1,593,000 | $-1,722,000 |
| Additional Paid In Capital | $2,736,994,000 | $2,736,994,000 | $2,735,557,000 | $2,730,391,000 |
| Capital Stock | $293,937,000 | $293,937,000 | $293,604,000 | $292,075,000 |
| Common Stock | $293,937,000 | $293,937,000 | $293,604,000 | $292,075,000 |
| Employee Benefits | $2,099,000 | $2,293,000 | $5,540,000 | $11,699,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,099,000 | $2,293,000 | $5,540,000 | $11,699,000 |
| Non Current Deferred Revenue | $838,876,000 | $1,071,193,000 | $1,623,599,000 | $1,944,836,000 |
| Long Term Capital Lease Obligation | $8,243,000 | $4,944,000 | $14,692,000 | $19,655,000 |
| Current Deferred Revenue | $232,476,000 | $256,270,000 | $365,631,000 | $419,866,000 |
| Current Capital Lease Obligation | $3,479,000 | $4,652,000 | $7,209,000 | $7,204,000 |
| Current Accrued Expenses | $1,092,000 | $548,000 | $651,000 | $3,114,000 |
| Investments And Advances | $253,123,000 | $13,575,000 | $0 | $0 |
| Goodwill | $70,010,000 | $69,557,000 | $69,813,000 | $0 |
| Net PPE | $122,898,000 | $126,321,000 | $154,253,000 | $137,513,000 |
| Accumulated Depreciation | $-53,052,000 | $-51,262,000 | $-61,110,000 | $-51,279,000 |
| Gross PPE | $175,950,000 | $177,583,000 | $215,363,000 | $188,792,000 |
| Leases | $24,585,000 | $23,174,000 | $34,834,000 | $37,461,000 |
| Other Properties | $8,605,000 | $14,673,000 | $24,529,000 | $71,101,000 |
| Machinery Furniture Equipment | $56,746,000 | $49,031,000 | $67,281,000 | $54,099,000 |
| Land And Improvements | $86,014,000 | $90,705,000 | $88,719,000 | $26,131,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $0 | $6,117,000 | $8,063,000 | $4,842,000 |
| Work In Process | $0 | $12,598,000 | $5,791,000 | $1,376,000 |
| Raw Materials | $51,192,000 | $55,263,000 | $39,071,000 | $14,351,000 |
| Other Short Term Investments | $3,053,334,000 | $3,517,698,000 | $3,585,945,000 | $2,469,809,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-402,136,000 | $-425,243,000 | $-537,491,000 | $-561,706,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-320,026,000 | $-405,970,000 | $-500,544,000 | $-503,827,000 |
| Cash Flow From Continuing Operating Activities | $-320,026,000 | $-405,971,000 | $-500,544,000 | $-503,827,000 |
| Operating Gains Losses | $-76,339,000 | $18,810,000 | $-42,043,000 | $-91,216,000 |
| Investing Activities | ||||
| Capital Expenditure | $-82,110,000 | $-19,273,000 | $-36,947,000 | $-57,879,000 |
| Investing Cash Flow | $220,597,000 | $71,186,000 | $-1,245,514,000 | $541,238,000 |
| Cash Flow From Continuing Investing Activities | $220,597,000 | $71,186,000 | $-1,245,514,000 | $541,239,000 |
| Net Other Investing Changes | - | - | $-10,000,000 | $-1,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-4,924,000 | $-5,001,000 | $-1,487,000 | $-3,876,000 |
| Cash Flow From Continuing Financing Activities | $-4,924,000 | $-5,001,000 | $-1,487,000 | $-3,876,000 |
| Net Other Financing Charges | - | $1,770,000 | $6,695,000 | $3,314,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-4,924,000 | $-6,771,000 | $-8,182,000 | $-7,190,000 |
| End Cash Position | $64,239,000 | $166,810,000 | $508,117,000 | $2,233,368,000 |
| Beginning Cash Position | $166,810,000 | $508,117,000 | $2,233,368,000 | $2,143,071,000 |
| Effect Of Exchange Rate Changes | $1,782,000 | $-1,522,000 | $22,293,000 | $56,763,000 |
| Changes In Cash | $-104,353,000 | $-339,785,000 | $-1,747,544,000 | $33,534,000 |
| Net Issuance Payments Of Debt | $-4,924,000 | $-6,771,000 | $-8,182,000 | $-7,190,000 |
| Net Long Term Debt Issuance | $-4,924,000 | $-6,771,000 | $-8,182,000 | $-7,190,000 |
| Long Term Debt Payments | $-4,924,000 | $-6,771,000 | $-8,182,000 | $-7,190,000 |
| Interest Received Cfi | $29,498,000 | $14,765,000 | $2,996,000 | $12,000 |
| Net Investment Purchase And Sale | $282,155,000 | $80,268,000 | $-1,087,032,000 | $570,410,000 |
| Sale Of Investment | $3,668,441,000 | $3,484,411,000 | $1,641,602,000 | $2,131,425,000 |
| Purchase Of Investment | $-3,386,286,000 | $-3,404,143,000 | $-2,728,634,000 | $-1,561,015,000 |
| Net Business Purchase And Sale | $-8,949,000 | $-7,000,000 | $-115,270,000 | $28,696,000 |
| Purchase Of Business | $-8,949,000 | $-7,000,000 | $-115,270,000 | $0 |
| Net Intangibles Purchase And Sale | $-65,390,000 | $-567,000 | $-9,558,000 | $-3,674,000 |
| Purchase Of Intangibles | $-65,390,000 | $-567,000 | $-9,558,000 | $-3,674,000 |
| Net PPE Purchase And Sale | $-16,717,000 | $-16,280,000 | $-26,650,000 | $-54,205,000 |
| Sale Of PPE | $3,000 | $2,426,000 | $739,000 | $0 |
| Purchase Of PPE | $-16,720,000 | $-18,706,000 | $-27,389,000 | $-54,205,000 |
| Taxes Refund Paid | $406,000 | $-8,170,000 | $-4,433,000 | $-684,000 |
| Interest Received Cfo | $97,518,000 | $69,907,000 | $4,839,000 | $2,913,000 |
| Interest Paid Cfo | $-689,000 | $-3,809,000 | $-12,463,000 | $-12,540,000 |
| Change In Working Capital | $-320,551,000 | $-692,435,000 | $-379,469,000 | $-430,382,000 |
| Change In Other Working Capital | $-255,508,000 | $-661,062,000 | $-383,618,000 | $-453,720,000 |
| Change In Other Current Liabilities | $-57,027,000 | $31,817,000 | $-30,247,000 | $-35,353,000 |
| Change In Inventory | $23,039,000 | $-24,076,000 | $-34,588,000 | $-21,168,000 |
| Change In Receivables | $-31,055,000 | $-39,114,000 | $68,984,000 | $79,859,000 |
| Other Non Cash Items | $-117,792,000 | $-91,719,000 | $1,029,000 | $18,728,000 |
| Stock Based Compensation | $19,886,000 | $56,718,000 | $88,506,000 | $70,726,000 |
| Unrealized Gain Loss On Investment Securities | $-49,984,000 | $-22,300,000 | $-6,929,000 | $4,800,000 |
| Asset Impairment Charge | $9,643,000 | $0 | $0 | - |
| Deferred Tax | $-1,705,000 | $11,689,000 | $2,844,000 | $2,423,000 |
| Deferred Income Tax | $-1,705,000 | $11,689,000 | $2,844,000 | $2,423,000 |
| Depreciation Amortization Depletion | $45,499,000 | $43,642,000 | $65,566,000 | $34,636,000 |
| Depreciation And Amortization | $45,499,000 | $43,642,000 | $65,566,000 | $34,636,000 |
| Depreciation | $45,499,000 | $43,642,000 | $65,566,000 | $34,636,000 |
| Pension And Employee Benefit Expense | $-524,000 | $11,000 | $136,000 | $-2,347,000 |
| Gain Loss On Investment Securities | $-4,000 | $-18,000 | $-186,000 | $-2,960,000 |
| Net Foreign Currency Exchange Gain Loss | $-23,858,000 | $19,908,000 | $-41,970,000 | $-63,718,000 |
| Gain Loss On Sale Of PPE | $8,000 | $-1,091,000 | $-23,000 | $0 |
| Gain Loss On Sale Of Business | $-51,961,000 | $0 | $0 | $-22,191,000 |
| Net Income From Continuing Operations | $74,082,000 | $211,697,000 | $-217,991,000 | $-103,231,000 |
| Sale Of Business | - | $0 | $0 | $28,696,000 |
| Other Cash Adjustment Outside Changein Cash | - | - | - | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
Fetched: 2026-02-02